[Amphiphilic cationic drug myopathy, drug-induced lysosomal storage lipidosis].
Kumamoto
T
T
Third Department of Internal Medicine, Oita Medical University.
D000634:Aminoquinolines / Q000009:adverse effects*; D000638:Amiodarone / Q000009:adverse effects*; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects*; D000962:Antimalarials / Q000009:adverse effects*; D001343:Autophagy; D002412:Cations; D002738:Chloroquine / Q000009:adverse effects*; D003937:Diagnosis, Differential; D006801:Humans; D006886:Hydroxychloroquine / Q000009:adverse effects*; D008247:Lysosomes / Q000187:drug effects / Q000473:pathology; D018482:Muscle, Skeletal / Q000166:cytology; D009135:Muscular Diseases / Q000139:chemically induced* / Q000473:pathology; D010480:Perhexiline / Q000009:adverse effects* / Q000031:analogs & derivatives*; D011379:Prognosis; D014617:Vacuoles / Q000473:pathology
D000634:Aminoquinolines; D000889:Anti-Arrhythmia Agents; D000962:Antimalarials; D002412:Cations; D006886:Hydroxychloroquine; D002738:Chloroquine; C023470:perhexiline maleate; D010480:Perhexiline; C057521:6-methoxy-8-(3-diethylaminopropylamino)quinoline; D000638:Amiodarone